Skip to main content
PMC home page
Journal of Urban Health : Bulletin of the New York Academy of Medicine logoLink to Journal of Urban Health : Bulletin of the New York Academy of Medicine
. 2004 Jun;81(2):278–290. doi: 10.1093/jurban/jth114

Screening for depressive symptoms among HCV-infected injection drug users: Examination of the utility of the CES-D and the beck depression inventory

Elizabeth T Golub 1,✉, Mary Latka 2, Holly Hagan 3, Jennifer R Havens 1, Sharon M Hudson 4, Farzana Kapadia 2, Jennifer V Campbell 5, Richard S Garfein 6, David L Thomas 7, Steffanie A Strathdee 1,8
PMCID: PMC3456451  PMID: 15136661

Abstract

The prevalence of depression is high among injection drug users (IDUs) and among those infected with the hepatitis C virus (HCV). Moreover, one of the drugs used in the standard treatment for HCV infection (interferon) has been known to exacerbate, underlying psychiatric disorders such as depression and has been associated with the development of major, depressive disorder among HCV-infected patients. For these reasons, the most recent National Institutes of Health consensus statement on the management of HCV infection recommends the identification and treatment of depression prior to the start of HCV treatment. This study aimed to examine the extent of current moderate/severe depressive symptoms in a cohort of HCV-infected IDUs as measured by two screening tools, the Center for Epidemiologic Studies Depression Scale (CES-D) and the Beck Depression Inventory (BDI). Subjects were participants in a multisite behavioral intervention trial among HCV-seropositive, human immunodeficiency virus-negative IDUs aged 18–35 years; the trial was designed to prevent secondary transmission of HCV and to enhance uptake of HCV treatment. Baseline data on demographics, risk behaviors, depression, alcohol use, and health care utilization were measured via audio computer-assisted self-interview. A factor analysis was conducted on each scale to examine the clustering of items used in each to measure depressive symptoms. Baseline depressive symptoms, as measured via the CES-D and the BDI, were also compared using Pearson’s correlation coefficient. Of 193 HCV-infected individuals enrolled to date, 75,6% were male, and 65.3% were white. Median age was 25.8 years. Factor analyses revealed that these scales measured depression differently; a distinct somatic component was present in the BDI, but not the CES-D. Using cutoff scores of 23 for the CES-D and 19 for the BDI, 44.0% and 41.5% of the participants were identified as having moderate/severe depressive symptoms, respectively. Over half (56.0%) were identified as having depressive symptoms

Full Text

The Full Text of this article is available as a PDF (115.6 KB).

References

  • 1.Centers for Disease Control and Prevention. Viral Hepatitis, and Injection Drug Users. 2002. Available at: www.cdc.gov/idu.
  • 2.Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–456. doi: 10.1001/jama.284.4.450. [DOI] [PubMed] [Google Scholar]
  • 3.Management of Hepatitis C: 2002. NIH Consens State Sci Statements. 2002 Jun 10–12; 19(3):1–41. [PubMed]
  • 4.Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345:211–215. doi: 10.1056/NEJM200107193450311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Management of Hepatitis C. NIH Consensus Statement 1997 Mar 24–26; 15(3):1–41. [PubMed]
  • 6.Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942–947. doi: 10.1038/sj.mp.4001119. [DOI] [PubMed] [Google Scholar]
  • 7.Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002;72:237–241. doi: 10.1016/S0165-0327(02)00264-1. [DOI] [PubMed] [Google Scholar]
  • 8.Khantizian EJ, Treece C. DSM-III psychiatric diagnoses of narcotic addicts. Arch Gen Psychiatry. 1985;42:1067–1071. doi: 10.1001/archpsyc.1985.01790340045007. [DOI] [PubMed] [Google Scholar]
  • 9.Ross HE, Glaser FB, Germanson F. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry. 1988;45:1023–1031. doi: 10.1001/archpsyc.1988.01800350057008. [DOI] [PubMed] [Google Scholar]
  • 10.Rounsaville BJ, Weissman MM, Kleber HD, et al. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry. 1982;39:161–166. doi: 10.1001/archpsyc.1982.04290020027006. [DOI] [PubMed] [Google Scholar]
  • 11.Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol. 1998;93:785–789. doi: 10.1111/j.1572-0241.1998.225_a.x. [DOI] [PubMed] [Google Scholar]
  • 12.Knowlton AR, Latkin CA, Schroeder JR, Hoover DR, Ensminger M, Celentano DD. Longitudinal predictors of depressive symptoms among low income injection drug users. AIDS Care. 2001;13:549–559. doi: 10.1080/09540120120063197. [DOI] [PubMed] [Google Scholar]
  • 13.Dinwiddie SH, Reich T, Cloninger CR. Psychiatric comorbidity and suicidality among intravenous drug users. J Clin Psychiatry. 1992;53:364–369. [PubMed] [Google Scholar]
  • 14.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994. [Google Scholar]
  • 15.Brienza RS, Stein MD, Chen M, et al. Depression among needle exchange program and methadone maintenance clients. J Subst Abuse Treat. 2000;18:331–337. doi: 10.1016/S0740-5472(99)00084-7. [DOI] [PubMed] [Google Scholar]
  • 16.Stein MD, Solomon DA, Herman DS, Anderson BJ, Miller I. Depression severity and drug injection HIV risk behaviors. Am J Psychiatry. 2003;160:1659–1662. doi: 10.1176/appi.ajp.160.9.1659. [DOI] [PubMed] [Google Scholar]
  • 17.Swartz MS, Swanson JW, Hannon MJ, et al. Blood-borne infections and persons with mental illness: regular sources of medical care among persons with severe, mental illness at risk of hepatitis C infection. Psychiatr Serv. 2003;54:854–859. doi: 10.1176/appi.ps.54.6.854. [DOI] [PubMed] [Google Scholar]
  • 18.Scalori A, Apale P, Panizzuti F, et al. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol. 2000;12:505–509. doi: 10.1097/00042737-200012050-00005. [DOI] [PubMed] [Google Scholar]
  • 19.Macalino GE, Celentano DD, Latkin C, Strathdee SA, Vlahov D. Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev. 2002;14:367–378. doi: 10.1521/aeap.14.6.367.24075. [DOI] [PubMed] [Google Scholar]
  • 20.Newman JC, Des J, Turner CF, Gribble J, Cooley P, Paone D. The differential effects of face-to-face and computer interview modes. Am J Public Health. 2002;92:294–297. doi: 10.2105/AJPH.92.2.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Metzger DS, Koblin B, Turner C, et al. Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am J Epidemiol. 2000;152:99–106. doi: 10.1093/aje/152.2.99. [DOI] [PubMed] [Google Scholar]
  • 22.HIV counseling, testing and referral standards and guidelines. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC; 1994. [Google Scholar]
  • 23.Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Measure. 1977;1:385–401. [Google Scholar]
  • 24.Clark CH, Mahoney JS, Clark DJ, Eriksen LR. Screening for depression in a hepatitis C population: the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D) J Adv Nurs. 2002;40:361–369. doi: 10.1046/j.1365-2648.2002.02378.x. [DOI] [PubMed] [Google Scholar]
  • 25.Roberts RE. Reliability of the CES-D scale in different ethnic contexts. Psychiatry Res. 1980;2:125–134. doi: 10.1016/0165-1781(80)90069-4. [DOI] [PubMed] [Google Scholar]
  • 26.Weissman MW, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ. Assessing depressive symptoms in five psychiatric populations, a validation study. Am J Epidemiol. 1977;106:203–214. doi: 10.1093/oxfordjournals.aje.a112455. [DOI] [PubMed] [Google Scholar]
  • 27.Perdue T, Hagan H, Thiede H, Valleroy L. Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men. AIDS Educ Prev. 2003;15:81–92. doi: 10.1521/aeap.15.1.81.23842. [DOI] [PubMed] [Google Scholar]
  • 28.Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571. doi: 10.1001/archpsyc.1961.01710120031004. [DOI] [PubMed] [Google Scholar]
  • 29.Joe GW, Knezek L, Watson D, Simpson DD. Depression and decision-making among intravenous drug users. Psychol Rep. 1991;68:339–347. doi: 10.2466/PR0.68.1.339-347. [DOI] [PubMed] [Google Scholar]
  • 30.Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: 25 years of evaluation. Clin Psychol Rev. 1988;8:77–100. doi: 10.1016/0272-7358(88)90050-5. [DOI] [Google Scholar]
  • 31.Shaw BF, Steer RA, Beck AT, Schut J. The structure of depression in heroin addicts. Br J Addict Alcohol Other Drugs. 1979;74:295–303. doi: 10.1111/j.1360-0443.1979.tb01351.x. [DOI] [PubMed] [Google Scholar]
  • 32.Reynolds WM, Gould JW. A psychometric investigation of the standard and short form Beck Depression Inventory. J Consult Clin Psychol. 1981;49:306–307. doi: 10.1037//0022-006X.49.2.306. [DOI] [PubMed] [Google Scholar]
  • 33.Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol. 2000;15:300–303. doi: 10.1046/j.1440-1746.2000.02090.x. [DOI] [PubMed] [Google Scholar]
  • 34.Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961–966. doi: 10.1056/NEJM200103293441303. [DOI] [PubMed] [Google Scholar]
  • 35.Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002;63:194–198. doi: 10.4088/jcp.v63n0304. [DOI] [PubMed] [Google Scholar]
  • 36.Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment a dherence and sustained response in chronic hepatitis C patients. Hepatology. 2002;35:704–8. doi: 10.1053/jhep.2002.31311. [DOI] [PubMed] [Google Scholar]
  • 37.Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443–451. doi: 10.1053/jhep.2003.50031. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES